Zynerba Pharmaceuticals, Inc
ZYNE
ZYNE was delisted on the 10th of October, 2023.
77 hedge funds and large institutions have $35.3M invested in Zynerba Pharmaceuticals, Inc in 2020 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 21 increasing their positions, 24 reducing their positions, and 14 closing their positions.
0% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 14
3% less funds holding
Funds holding: 79 → 77 (-2)
13% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 24
46% less capital invested
Capital invested by funds: $64.8M → $35.3M (-$29.5M)
50% less call options, than puts
Call options by funds: $1.08M | Put options by funds: $2.15M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prentice Capital Management
Greenwich,
Connecticut
|
+$612K |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$465K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$387K |
| 4 |
PCM
Penserra Capital Management
Orinda,
California
|
+$292K |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$192K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EMG
ETF Managers Group
Summit,
New Jersey
|
-$3.85M |
| 2 |
Morgan Stanley
New York
|
-$1.96M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$969K |
| 4 |
SC
Sculptor Capital
New York
|
-$674K |
| 5 |
Two Sigma Investments
New York
|
-$420K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AC
76
Aristides Capital
Louisville,
Kentucky
| – | -$160K | -26,518 | Closed |
|
|
GCP
77
GSA Capital Partners
London,
United Kingdom
| – | -$134K | -22,106 | Closed |
|
78
Squarepoint
New York
| – | -$104K | -17,254 | Closed |
|
|
ECM
79
ExodusPoint Capital Management
New York
| – | -$80K | -13,290 | Closed |
|
80
Capital Fund Management (CFM)
Paris,
France
| – | -$71K | -11,775 | Closed |
|
81
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$65K | -10,800 | Closed |
|
|
ARTA
82
A.R.T. Advisors
New York
| – | -$62K | -10,272 | Closed |
|
83
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$49K | -8,105 | Closed |
|
|
TRCT
84
Tower Research Capital (TRC)
New York
| – | -$26K | -4,250 | Closed |
|
|
AIC
85
Archer Investment Corporation
Carmel,
Indiana
| – | -$1K | -200 | Closed |
|
|
HR
86
Howe & Rusling
Rochester,
New York
| – | -$1K | -165 | Closed |
|
|
VNA
87
Valley National Advisers
Bethlehem,
Pennsylvania
| – | +$46 | +10 | New |
|
|
OPS
88
Orion Portfolio Solutions
Omaha,
Nebraska
| – | +$93 | +20 | New |
|
|
FWM
89
Filbrandt Wealth Management
Middleton,
Wisconsin
| – | +$348 | +75 | New |
|
ZYNE Hedge Fund Activity: Q1 2020 in Review
77 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Zynerba Pharmaceuticals, Inc (ZYNE) for Q1 2020, worth a combined $35.3M — down 46% from $64.8M a quarter earlier.
Fund positioning in ZYNE was balanced in Q1 2020: 14 funds opened new positions, 14 closed out, 21 added to existing stakes and 24 trimmed.
The largest buyer was Prentice Capital Management, adding an estimated $612K. The largest seller was ETF Managers Group, cutting an estimated $3.85M.
- 77 institutional investors held Zynerba Pharmaceuticals, Inc (ZYNE) as of Q1 2020, down from 79 in Q4 2019.
- Funds reported $35.3M of Zynerba Pharmaceuticals, Inc stock for Q1 2020, down 46% quarter-over-quarter.
- 14 funds opened new Zynerba Pharmaceuticals, Inc positions in Q1 2020 and 14 closed out, a net change of 0 holders.
- The largest Zynerba Pharmaceuticals, Inc buyer in Q1 2020 was Prentice Capital Management, an estimated $612K added.
- The largest Zynerba Pharmaceuticals, Inc seller in Q1 2020 was ETF Managers Group, an estimated $3.85M sold.
Based on aggregated 13F filings for Q1 2020.